The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

So, one of the areas of highest unmet needs in triple-negative breast cancer is the recurrence post-chemo and immunotherapy ...

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment for advanced penile cancer in a phase 2 trial. The results were published in JAMA Oncology.

The LITESPARK-022 and LITESPARK-011 trials evaluated combination regimens containing belzutifan in patients with advanced clear cell RCC.

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Background: Combination therapy with the ...

Anixa Biosciences to present a more complete phase 1 data readout at SABCS in December. Read my ANIX stock update and know ...

The impact of induction chemotherapy response to survival outcomes in oropharyngeal cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full ...

The addition of pembrolizumab (Keytruda) to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) did not improve overall or radiographic progression-free survival versus ...